Cretostimogene: 75% CR in BCG-Unresponsive Bladder Cancer

원문 링크: WordPress 원문

Investigators in the BOND-003 trial group reported in The Lancet Oncology on July 28, 2026 , that intravesical cretostimogene grenadenorepvec produced a 75% complete response rate in patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ . The single-arm design without a comparator leaves the durability of response and comparative advantage over existing salvage options uncertain , though the results position cretostimogene as a potential bladder-sparing alternative for patients who have exhausted BCG therapy .

The full phase 3 BOND-003 Cohort C dataset was published in The Lancet Oncology on July 28, 2026, providing the first peer-reviewed primary endpoint report for this oncolytic immunotherapy .

75%

Complete response rate

112

Patients received treatment

25.8 months

Median follow-up

English

한국어

Complete response reached three quarters of treated patients

Design: Single-arm, international, phase 3 trial across 41 centres in North America, Asia, and Australia.

Enrolled: 115 patients enrolled; 112 received cretostimogene.

Analysis population: Primary endpoint analysed in 110 patients; safety assessed in 112.

Primary endpoint: Centrally confirmed complete response at any time.

Among the 110 patients evaluable for the primary endpoint, 83 achieved a centrally confirmed complete response at any time, corresponding to a rate of 75% (95% CI 66.3–83.2). The treatment consisted of intravesical cretostimogene grenadenorepvec, an oncolytic adenovirus engineered to replicate selectively in tumour cells, delivered as a six-week induction course followed by a maintenance schedule. Re-induction was permitted for patients with persistent disease at the three-month assessment. The median age of participants was 74 years, and 74% were male, reflecting the typical demographic profile of high-risk non-muscle-invasive bladder cancer. All responses were adjudicated by an independent central review committee rather than by local site investigators, reducing assessment bias. The median follow-up of 25.8 months (IQR 22.1–33.1) provides a reasonable but not yet mature window for evaluating the durability of the observed responses. Extended surveillance will therefore be essential before these early response figures can be considered definitive across all participating sites.

AI-generated conceptual illustration; not study data.

A potential bladder-sparing option after BCG failure

Patients with BCG-unresponsive non-muscle-invasive bladder cancer face a narrow set of options. The current standard of care for those who cannot or will not undergo radical cystectomy includes pembrolizumab, which carries an overall response rate of roughly 41% in this setting, and nadofaragene firadenovec, a gene therapy approved in the United States. Cretostimogene represents a different mechanistic approach: an oncolytic virus that directly lyses tumour cells while simultaneously stimulating a local anti-tumour immune response. The 75% complete response rate observed in BOND-003 Cohort C is numerically higher than what has been reported for these existing agents, although cross-trial comparisons are inherently limited by differences in patient selection, endpoint definitions, and follow-up duration. For patients who wish to preserve their bladder and maintain quality of life, a therapy with this level of activity and a manageable safety profile could shift the treatment landscape. The international, multicentre design of the trial also strengthens the generalisability of the findings across diverse clinical settings and patient populations. Such breadth also helps clinicians judge whether the observed activity would hold in routine practice beyond specialised trial centres.

Safety profile was manageable but durability data remain limited

The most frequently reported treatment-related adverse events were bladder spasm (25%), pollakiuria (22%), and micturition urgency (21%), consistent with the local irritative effects expected from an intravesical agent. Importantly, there were no grade 3 or 4 treatment-related adverse events, no treatment-related discontinuations, and no treatment-related deaths across the 112 patients who received at least one dose. Two patients experienced serious treatment-related adverse events, both graded as grade 2: one case of non-infective cystitis and one case of urinary bladder haemorrhage. While this safety profile is reassuring, the single-arm design means there is no concurrent comparator to contextualise these rates against standard surveillance or alternative therapies. The median follow-up of approximately 26 months is insufficient to characterise long-term recurrence patterns or late-onset toxicities. Additionally, the trial enrolled only patients with carcinoma in situ, so the results cannot be extrapolated to papillary-only disease. The study was funded by CG Oncology, the developer of cretostimogene, which introduces a potential conflict of interest that readers should weigh when interpreting the findings. Independent replication in a randomised setting would further clarify the true magnitude of both benefit and risk.

AI-generated conceptual illustration; not study data.

Regulatory review and longer follow-up will determine clinical impact

The BOND-003 trial is ongoing, and longer follow-up will be essential to determine whether the initial complete responses translate into durable disease control and reduced progression to muscle-invasive disease. Regulatory submissions will depend on the totality of evidence, including durability endpoints and post-marketing safety commitments. Cretostimogene grenadenorepvec has not yet received marketing approval in any jurisdiction, and its eventual role in the treatment algorithm will depend on head-to-head or indirect comparative data against pembrolizumab and nadofaragene firadenovec. Clinicians should note that registration in a clinical trial does not constitute a confirmed clinical benefit, and that the absence of a comparator arm limits the strength of any efficacy claim. Patients and caregivers should discuss individual treatment options with their urologic oncology team rather than relying on single-trial results. The next critical milestones include the publication of extended follow-up data and any regulatory decisions by the United States Food and Drug Administration or the European Medicines Agency. Continued pharmacovigilance and patient-reported outcome collection will round out the evidence needed for informed clinical adoption.

This article reports results from a single-arm phase 3 trial without a randomised comparator. A complete response rate observed in an uncontrolled setting cannot be directly attributed to the intervention without accounting for natural history, selection bias, and assessment effects. Association between treatment and outcome does not establish causation. Biomarker or response endpoints do not constitute a definitive diagnosis of cure.

References

PubMed: PMID 42508433 — BOND-003 Cohort C, Lancet Oncology 2026

DOI: 10.1016/S1470-2045(26)00194-4 — Full article

This content is for informational purposes only and is not medical advice. Treatment decisions should be made in consultation with a qualified healthcare professional. Clinical trial registration does not equal confirmed clinical benefit. Authorisation in one jurisdiction does not imply approval elsewhere.